

Bill Summary
2nd Session of the 58th Legislature

Bill No.:	SB 1467
Version:	INT
Request No.:	2571
Author:	Sen. David
Date:	01/20/2022

Bill Analysis

SB 1467 directs the Oklahoma Health Care Authority to conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease. The review shall examine the extent to which healthcare transitional programs prepare, transfer, and integrate emerging adults into the adult care setting, extent to which emergency department providers are adequately trained to treat the disease, extent to which sickle cell patients are entitled to receive the same standard of care when referred or transferred to an out-of-state facility, and additional areas of interest identified by the Authority. The Authority is directed to solicit opinions from the general public as it conducts the study. Additionally, the Authority shall utilize the Oklahoma State Health Information Network and Exchange to the extent practicable. The report shall be published on the Authority's website as well as provided to the President Pro Tempore of the Senate, Speaker of the House, and Governor on January 15, 2023, and each January 15 thereafter.

Prepared by: Kalen Taylor